Patents Assigned to Kissei Pharmaceutical Co., Ltd.
  • Publication number: 20200390768
    Abstract: The present invention provides 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyl-oxy)-4-methoxyphenyl]-2,4-dioxo-1,2,3,4-tetrahydrothieno[3,4-d]pyrimidine-5-carboxylic acid choline salt having excellent solubility and storage stability.
    Type: Application
    Filed: January 21, 2020
    Publication date: December 17, 2020
    Applicant: KISSEI PHARMACEUTICAL CO., LTD.
    Inventors: Kazumichi JO, Hideki TAKEUCHI
  • Publication number: 20200299273
    Abstract: The present invention aims to provide a novel compound which has CGRP receptor antagonist activity and which is useful for the treatment of various diseases mediated by CGRP receptors. That is, the present invention relates to the pyrrolidine derivatives represented by the following formula (I) or a pharmaceutically acceptable salt thereof. In the formulae, W is ring, X is a carbon atom or the like, Y1 to Y4 are carbon atoms or the like, and R1 to R7 is alkyl or the like. The compounds of the present invention or a pharmaceutically acceptable salt thereof have an excellent CGRP receptor antagonist activity, and thus are useful as agents for the treatment of various diseases mediated by CGRP receptors.
    Type: Application
    Filed: July 20, 2017
    Publication date: September 24, 2020
    Applicant: KISSEI PHARMACEUTICAL CO., LTD.
    Inventors: Atsushi Kondo, Naohide Morita, Takehiro Ishikawa, Masako Yoshida, Akihiro Moriyama, Isao Wanajo
  • Patent number: 10683355
    Abstract: Production of a chimeric antigen receptor (CAR) expressing cell having excellent target cytotoxicity. Provided is a genetically modified cell comprising, introduced thereinto, a polynucleotide encoding a chimeric antigen receptor (CAR) protein having a target binding domain that specifically binds to a human granulocyte-macrophage colony stimulating factor (GM-CSF) receptor, a transmembrane domain and an intracellular signaling domain.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: June 16, 2020
    Assignees: KISSEI PHARMACEUTICAL CO., LTD., SHINSHU UNIVERSITY
    Inventors: Yozo Nakazawa, Kazuyuki Matsuda, Shigeru Nakano
  • Patent number: 10646491
    Abstract: An object of the present invention is to provide pharmaceutical agents that reduce risk for decrease in bone mineral density due to their effect of reducing estrogen levels and exert excellent therapeutic effects on endometriosis. The present invention relates to pharmaceutical compositions for treating endometriosis comprising 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyloxy)-4-methoxyphenyl]-2,4-dioxo-1,2,3,4-tetrahydrothieno[3,4-d]pyrimidine-5-carboxylic acid or a pharmaceutically acceptable salt thereof, which are administered orally once a day at a daily dose of between 50 mg and 75 mg calculated as a free form.
    Type: Grant
    Filed: August 7, 2017
    Date of Patent: May 12, 2020
    Assignee: KISSEI PHARMACEUTICAL CO., LTD.
    Inventors: Takuro Dan, Hideomi Takahashi, Yu Kuramochi
  • Patent number: 10576084
    Abstract: The present invention provides 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyl-oxy)-4-methoxyphenyl]-2,4-dioxo-1,2,3,4-tetrahydrothieno[3,4-d]pyrimidine-5-carboxylic acid choline salt having excellent solubility and storage stability.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: March 3, 2020
    Assignee: KISSEI PHARMACEUTICAL CO., LTD.
    Inventors: Kazumichi Jo, Hideki Takeuchi
  • Patent number: 10399949
    Abstract: A problem of the present invention is to provide a new compound which has NK1 receptor antagonist activity, and thus is useful for the prevention or treatment of cancer-chemotherapy-induced nausea and vomiting. A compound represented by the formula (I): wherein W represents a fluorine atom and the like, ring A represents a cycloalkyl and the like, X1 represents CH or N, R represents methyl and the like, Y represents 0 to 2, U1, U2 and U3 each independently represents a single bond and the like, or a pharmaceutically acceptable salt thereof. The compounds of the present invention or pharmaceutically acceptable salts thereof have an excellent NK1 receptor antagonist activity, and thus are also useful as an agent for the prevention or treatment of cancer-chemotherapy-induced nausea and vomiting.
    Type: Grant
    Filed: December 6, 2016
    Date of Patent: September 3, 2019
    Assignee: KISSEI PHARMACEUTICAL CO., LTD.
    Inventors: Takashi Miyagi, Masahiro Kobayashi, Toshihiro Nishimura
  • Publication number: 20190202923
    Abstract: Production of a chimeric antigen receptor (CAR) expressing cell having excellent target cytotoxicity. Provided is a genetically modified cell comprising, introduced thereinto, a polynucleotide encoding a chimeric antigen receptor (CAR) protein having a target binding domain that specifically binds to a human granulocyte-macrophage colony stimulating factor (GM-CSF) receptor, a transmembrane domain and an intracellular signaling domain.
    Type: Application
    Filed: September 15, 2017
    Publication date: July 4, 2019
    Applicants: KISSEI PHARMACEUTICAL CO., LTD., SHINSHU UNIVERSITY
    Inventors: Yozo Nakazawa, Kazuyuki Matsuda, Shigeru Nakano
  • Publication number: 20190175600
    Abstract: An object of the present invention is to provide pharmaceutical agents that reduce risk for decrease in bone mineral density due to their effect of reducing estrogen levels and exert excellent therapeutic effects on endometriosis. The present invention relates to pharmaceutical compositions for treating endometriosis comprising 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyloxy)-4-methoxyphenyl]-2,4-dioxo-1,2,3,4-tetrahydrothieno[3,4-d]pyrimidine-5-carboxylic acid or a pharmaceutically acceptable salt thereof, which are administered orally once a day at a daily dose of between 50 mg and 75 mg calculated as a free form.
    Type: Application
    Filed: August 7, 2017
    Publication date: June 13, 2019
    Applicant: KISSEI PHARMACEUTICAL CO., LTD.
    Inventors: Takuro Dan, Hideomi Takahashi, Yu Kuramochi
  • Patent number: 10287251
    Abstract: The present invention is to provide a novel pyrazole derivative, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same, and a pharmaceutical use thereof. The present invention provides a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof, which has TRPM8 inhibitory effects: wherein ring A is C6-10 aryl or the like; X is CR4a or the like; R1 and R2 are a hydrogen atom or the like; R3 is a hydrogen atom or the like; R4 is a hydrogen atom or the like; ring B is C6-10 aryl or the like; R5 is a hydrogen atom or the like; R6a is a hydrogen atom or the like; R7a is a hydrogen atom or the like; R7b is a hydrogen atom or the like; R6b is a hydrogen atom or the like; R8 is a hydrogen atom or the like; n is 0, 1 or 2.
    Type: Grant
    Filed: June 22, 2016
    Date of Patent: May 14, 2019
    Assignee: KISSEI PHARMACEUTICAL CO., LTD.
    Inventors: Hideaki Hirasawa, Fumiya Tanada, Yousuke Mutai, Nobuhiko Fushimi, Junichi Kobayashi, Yoshiro Kijima
  • Publication number: 20190134038
    Abstract: The present invention provides 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyl-oxy)-4-methoxyphenyl]-2,4-dioxo- 1,2,3,4-tetrahydrothieno [3 ,4-d]pyrimidine-5-carboxylic acid choline salt having excellent solubility and storage stability.
    Type: Application
    Filed: June 27, 2018
    Publication date: May 9, 2019
    Applicant: KISSEI PHARMACEUTICAL CO., LTD.
    Inventors: Kazumichi JO, Hideki TAKEUCHI
  • Publication number: 20190002414
    Abstract: A problem of the present invention is to provide a new compound which has NK1 receptor antagonist activity, and thus is useful for the prevention or treatment of cancer-chemotherapy-induced nausea and vomiting. A compound represented by the formula (I): wherein W represents a fluorine atom and the like, ring A represents a cycloalkyl and the like, X1 represents CH or N, R represents methyl and the like, Y represents 0 to 2, U1, U2 and U3 each independently represents a single bond and the like, or a pharmaceutically acceptable salt thereof. The compounds of the present invention or pharmaceutically acceptable salts thereof have an excellent NK1 receptor antagonist activity, and thus are also useful as an agent for the prevention or treatment of cancer-chemotherapy-induced nausea and vomiting.
    Type: Application
    Filed: December 6, 2016
    Publication date: January 3, 2019
    Applicant: KISSEI PHARMACEUTICAL CO., LTD.
    Inventors: Takashi Miyagi, Masahiro Kobayashi, Toshihiro Nishimura
  • Publication number: 20180312566
    Abstract: Provided is an Fc fusion high affinity IgE receptor ?-chain having excellent stability at low pH. An Fc fusion protein comprising: (i) a high affinity IgE receptor ?-chain; and (ii) an Fc region of IgG1, wherein a linker fragment region between the (i) and the (ii) is the amino acid sequence shown in SEQ ID NO: 2.
    Type: Application
    Filed: July 13, 2018
    Publication date: November 1, 2018
    Applicant: Kissei Pharmaceutical Co., Ltd.
    Inventors: Takashi Sakamoto, Yoichi Inada, Kazumasa Yokoyama
  • Patent number: 10100030
    Abstract: The present invention provides a new compound which has NK1 receptor antagonist activity, whose CYP3A4 inhibitory activity is reduced compared to aprepitant, and which are useful for the prevention or treatment of cancer-chemotherapy-induced nausea and vomiting. That is, the present invention relates to carboxymethyl piperidine derivatives represented by the following formula (I) or a pharmaceutically acceptable salt thereof. Wherein, ring A is a benzene ring or the like; ring B is a pyridine ring or the like; R1 is C1-6 alkyl or C1-6 alkoxy; R2 and R3 are a hydrogen atom or methyl; and n is an integral number from 0 to 5.
    Type: Grant
    Filed: November 6, 2014
    Date of Patent: October 16, 2018
    Assignee: KISSEI PHARMACEUTICAL CO., LTD.
    Inventors: Kazuo Shimizu, Takashi Miyagi, Kohsuke Ohno, Yasunori Ueno, Yusuke Onda, Hikaru Suzuki
  • Patent number: 10077297
    Abstract: Provided is an Fc fusion high affinity IgE receptor ?-chain having excellent stability at low pH. An Fc fusion protein comprising: (i) a high affinity IgE receptor ?-chain; and (ii) an Fc region of IgG1, wherein a linker fragment region between the (i) and the (ii) is the amino acid sequence shown in SEQ ID NO: 2.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: September 18, 2018
    Assignee: Kissei Pharmaceutical Co., Ltd.
    Inventors: Takashi Sakamoto, Yoichi Inada, Kazumasa Yokoyama
  • Patent number: 10047139
    Abstract: Provided is an Fc fusion high affinity IgE receptor ?-chain having excellent stability at low pH. An Fc fusion protein comprising: (i) a high affinity IgE receptor ?-chain; and (ii) an Fc region of IgG1, wherein a linker fragment region between the (i) and the (ii) is the amino acid sequence shown in SEQ ID NO: 2.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: August 14, 2018
    Assignee: Kissei Pharmaceutical Co., Ltd.
    Inventors: Takashi Sakamoto, Yoichi Inada, Kazumasa Yokoyama
  • Patent number: 10016433
    Abstract: The present invention provides 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyl-oxy)-4-methoxyphenyl]-2,4-dioxo-1,2,3,4-tetrahydrothieno[3,4-d]pyrimidine-5-carboxylic acid choline salt having excellent solubility and storage stability.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: July 10, 2018
    Assignee: KISSEI PHARMACEUTICAL CO., LTD.
    Inventors: Kazumichi Jo, Hideki Takeuchi
  • Patent number: 10011568
    Abstract: A problem of the present invention is to provide a new compound which has NK1 receptor antagonist activity, whose CYP3A4 inhibitory activity is reduced compared to aprepitant, and which are useful for the prevention or treatment of cancer-chemotherapy-induced nausea and vomiting. That is, the present invention relates to cyclohexyl pyridine derivatives represented by the following formula (I) or a pharmaceutically acceptable salt thereof, wherein, ring A is 4-fluoro-2-methylphenyl or the like; X is a hydrogen atom or the like; R1 is carboxymethyl or the like; R2 is alkyl or the like; Y is 0-2 or the like; U is —N(CH3)COC(CH3)2-3,5-bistrifluoromethylphenyl or the like.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: July 3, 2018
    Assignee: KISSEI PHARMACEUTICAL CO., LTD.
    Inventors: Kazuo Shimizu, Kohsuke Ohno, Takashi Miyagi, Yasunori Ueno, Hikaru Suzuki
  • Publication number: 20180170879
    Abstract: [Problem] The present invention is to provide a novel pyrazole derivative, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same, and a pharmaceutical use thereof. [Solution] The present invention provides a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof, which has TRPM8 inhibitory effects: wherein ring A is C6-10 aryl or the like; X is CR4a or the like; R1 and R2 are a hydrogen atom or the like; R3 is a hydrogen atom or the like; R4 is a hydrogen atom or the like; ring B is C6-10 aryl or the like; R5 is a hydrogen atom or the like; R6a is a hydrogen atom or the like; R7a is a hydrogen atom or the like; R7b is a hydrogen atom or the like; R6b is a hydrogen atom or the like; R8 is a hydrogen atom or the like; n is 0, 1 or 2.
    Type: Application
    Filed: June 22, 2016
    Publication date: June 21, 2018
    Applicant: KISSEI PHARMACEUTICAL CO., LTD.
    Inventors: Hideaki HIRASAWA, Fumiya TANADA, Yousuke MUTAI, Nobuhiko FUSHIMI, Junichi KOBAYASHI, Yoshiro KIJIMA
  • Patent number: 9988350
    Abstract: The present invention provides a compound represented by the general formula (I): in the formula, R1, R2 and R3 are each a hydrogen atom, a halogen atom, a C1-6 alkyl group, a halo C1-6 alkyl group or the like, R4 is a C1-6 alkyl group or the like, R5 is a C1-6 alkyl group or the like, R6 is a C1-6 alkyl group or the like, R7 is a hydrogen atom, a halogen atom, a C1-6 alkyl group or the like, R8 is a halogen atom, a C1-6 alkyl group, a halo C1-6 alkyl group, a C1-6 alkoxy group or the like, and R9 is a hydrogen atom or a C1-6 alkyl group, or a pharmaceutically acceptable salt thereof. The compounds of the present invention have an excellent S1P1 receptor antagonistic activity and therefore are useful as an agent for the treatment or prevention of autoimmune diseases and the like.
    Type: Grant
    Filed: July 26, 2017
    Date of Patent: June 5, 2018
    Assignee: KISSEI PHARMACEUTICAL CO., LTD.
    Inventors: Hitoshi Inoue, Kohsuke Ohno, Tetsuya Nakamura, Yusuke Ohsawa
  • Publication number: 20180147189
    Abstract: The present invention is directed to provide excellent pharmaceutical compositions for the treatment of ataxia in spinocerebellar degeneration with which the risk of side effects caused by elevation of thyroid hormone levels is reduced. The present invention relates to a pharmaceutical composition for treatment of ataxia in spinocerebellar degeneration including, as an active ingredient, a daily dose of 1.6 mg to 3.2 mg of rovatirelin or 1.6 mg to 3.2 mg of pharmacologically acceptable salt of rovatirelin as being calculated as a free form, wherein the pharmaceutical composition is administered once daily. The pharmaceutical compositions of the present invention are particularly useful as therapeutic agents for ataxia in SCD.
    Type: Application
    Filed: June 26, 2015
    Publication date: May 31, 2018
    Applicant: KISSEI PHARMACEUTICAL CO., LTD.
    Inventors: Yoshitaka Shimizu, Hitoshi Yamano, Yuji Kiyono, Tomoyuki Ijiro